<code id='B5D56697C6'></code><style id='B5D56697C6'></style>
    • <acronym id='B5D56697C6'></acronym>
      <center id='B5D56697C6'><center id='B5D56697C6'><tfoot id='B5D56697C6'></tfoot></center><abbr id='B5D56697C6'><dir id='B5D56697C6'><tfoot id='B5D56697C6'></tfoot><noframes id='B5D56697C6'>

    • <optgroup id='B5D56697C6'><strike id='B5D56697C6'><sup id='B5D56697C6'></sup></strike><code id='B5D56697C6'></code></optgroup>
        1. <b id='B5D56697C6'><label id='B5D56697C6'><select id='B5D56697C6'><dt id='B5D56697C6'><span id='B5D56697C6'></span></dt></select></label></b><u id='B5D56697C6'></u>
          <i id='B5D56697C6'><strike id='B5D56697C6'><tt id='B5D56697C6'><pre id='B5D56697C6'></pre></tt></strike></i>

          explore

          explore

          author:leisure time    Page View:957
          The FDA building -- First Opinion coverage from STAT
          Adobe

          A panel of independent advisers to the Food and Drug Administration voted overwhelmingly against a polarizing potential treatment for ALS on Wednesday, concluding that the medicine’s messy supporting data did not meet the standard for approval.

          After a day-long meeting that included impassioned testimony from ALS patients, the agency’s expert advisers voted 17-1 with one abstention that the case for NurOwn, a treatment from BrainStorm Cell Therapeutics, was based too heavily on convoluted clinical trial results and compelling but unreliable anecdotal evidence.

          advertisement

          “Patients and families need hope, but providing false hope can be ethically problematic,” said panelist Lisa Lee, a bioethicist at Virginia Tech. “False hope is provided when the probability of a positive outcome is overestimated, and I think that seems to be the case here.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more
          Mirador, a new biotech startup, launches with $400 million
          Mirador, a new biotech startup, launches with $400 million

          AdobeWhathappensafteryoucloseanearly$11billionacquisition?Well,forPrometheusTherapeutics’formerCEOMa

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          How to use technology to prevent future drug shortages

          TherehasbeenapersistentshortageoftheADHDdrugAdderall.JennyKane/APMyfirstexposuretopharmaceuticalshor